Anti-Human clfA/Clumping factor A Reference Antibody (Tefibazumab, RUO) (JN060016)

Name: Anti-Human clfA/Clumping factor A Reference Antibody (Tefibazumab, RUO)
Brand: abinScience
SKU: JN060016
Price: 176 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	JN060016
Descripción	Tefibazumab (JN060016) is a research-grade recombinant antibody targeting clfAClumping factor A. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especies	Staphylococcus aureus
Aplicaciones	ELISA, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG1-kappa
Sistema de expresión	Mammalian cells
Objetivo	clfA Clumping factor A
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% purity as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	Q53653, Q2G015, Q5HHM8
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4 Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	Aurexis, 521079-87-8
Fondo	Clumping factor A (clfAClumping factor A) is a ~97 kDa protein. Cell surface-associated protein implicated in virulence. Promotes bacterial attachment exclusively to the gamma-chain of human fibrinogen. Induces formation of bacterial clumps, which diminish the ability of group IIA phospholipase A2 to cause bacterial phospholipid hydrolysis and killing. Significantly decreases macrophage phagocytosis possibly thanks to the clumps, clumped bacteria being too large to be phagocytosed. Dominant factor responsible for human platelet aggregation, which may be an important mechanism for initiating infective endocarditis.
Nota	For research use only. Not suitable for clinical or therapeutic use.

Imágenes

Bioactivity

SEC-HPLC detection for Research Grade Tefibazumab.
SDS-PAGE

SDS-PAGE for Research Grade Tefibazumab.

Referencias

Datasheet

Anti-Human clfA/Clumping factor A Reference Antibody (Tefibazumab, RUO).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Proteínas Recombinantes

Anticuerpos

Kits de Ensayo